Cold Genesys looks to China for a $10M cash infusion

Immuno-oncology biotech Cold Genesys raised a $10 million B round, rallying a stable of Chinese financiers as it moves forward with a late-stage cancer therapy. WI Harper Group co-led the round with Ally Bridge Group, the Hong Kong-headquartered investor that put up $13.6 million for Cold Genesys' A round last year. The funds will support the biotech's ongoing development of CG0070, an oncolytic virus wired to kill tumors with a dual mechanism of action, first multiplying within the cell to disrupt growth pathways, and then expressing the gene GM-CSF to recruit the body's dendritic cells and T cells. The treatment is now in pivotal trials in bladder cancer with data expected in 2018. More